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The 4p16 genomic region involved in t(4;14) is linked with a number of human genetic disorders including Huntington's Disease, Wolf-Hirschhorns (WHS) Disease, and the autosomal dominant skeletal disorders (hypochondroplasia, achondroplasia, thanatophoric dysplasia type I and II). The skeletal disorders are linked to activating mutations of FGFR3. 17 Some of these mutations are found in 5-10% of the FGFR3 expressing t(4;14) POS MM patients. [18] [19] [20] The minimally deleted WHS critical region of 165 kb contains two genes; WHSC1/MMSET/NSD2 and WHSC2. [21] [22] [23] Two different transcripts are transcribed from the MMSET gene. The first originates upstream of the proper translation initiation site and is alternatively spliced into three mRNA species MMSET type I, MMSET type II, and MMSET type III. 13, 15, 22 MMSET II, the full length protein, likely regulates gene expression by modifying histone methylation patterns.
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The second transcript originates within intron 9 of the MMSET gene. 25 Translation of this transcript initiates in exon 15 and produces the protein RE-IIBP, which is identical to the C-terminus of MMSET II.
Here we show by quantitative RT-PCR (qRT-PCR) analysis that the overexpression of both MMSET splice variants and RE-IIBP is the only unique characteristic of all t(4;14) POS patients. Furthermore, we show that all MMSET breakpoint variants and RE-IIBP transcripts produce protein products. However, the MB4-2/MB4-3 breakpoint variants localize differently from the wild-type/MB4-1 proteins and have altered kinetics within the nucleoplasm. Alternatively, RE-IIBP is universally overexpressed and encodes the proper full length protein in all t(4;14)
POS patients.
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Materials and Methods
Patient Samples and Cell Lines
The study was approved by the University of Alberta/Capital Health Authority and Alberta Cancer Board research ethics boards. Bone marrow (BM) aspirates were obtained from 304 MM and 112 monoclonal gammopathy of undetermined significance (MGUS) patients after informed consent. Daudi, Raji, RPMI-8226, U266, KMS-12-BM, KMS-12-PE, KMS-11, NCI-H929, and JIM3 cell lines were maintained as previously described. 12, 13 The OPM-2 and LP-1 cell lines were purchased from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). The KMS-18 cell line was a kind gift from Takemi Otsuki (Kawasaki Medical School). 26 
Sample Purification
Bone marrow mononuclear cells (BMMC) were purified on Ficoll-Hypaque Plus (Amersham-Pharmacia Biotech, Uppsala, Sweden) density gradients using standard conditions. For bulk BM RNA samples, 2-10 million cells were suspended in Trizol Reagent (Invitrogen, Carlsbad, CA). Plasma cells were purified on an Automacs Magnetic Cell Separator (Miltenyi Biotec, Auburn, CA) using anti-CD138 microbeads.
Alternatively, plasma cells with a CD38
hi and CD138 + phenotype were sorted on an Epics® Altra™ Flow Cytometer (Beckman-Coulter, Fullerton, CA). The purity of all sorted samples where verified to be greater than 90% by morphological examination.
Polymerase Chain Reactions
The reaction conditions and primers used to detect t(4;14) and FGFR3 were described previously. 12 For qRT-PCR, 1 µg of total RNA was first treated with 1 Unit of 
Expression Vector Construction
The open reading frames (ORF) of MMSET I and MMSET II obtained from PLB were PCR amplified with High Fidelity Platinum Taq DNA polymerase (Invitrogen) using primers indicated in Table 1 and cloned into pCR4.0-TOPO (Invitrogen).
The NdeI/XhoI and NdeI/∆stop-XhoI cloned fragments were transferred by site directed cloning to pDNR-3 or pDNR-Dual, respectively, of the Creator™ Cloning System (BD Biosciences, San Jose, CA ). The ORF of interest was then transferred from 
Statistics
Survival statistics were performed as previously described. 12 Student t-tests were calculated with Excel (Microsoft, Redmond, WA) using an unpaired two-sided analysis. Figure 2B ). Therefore, neither the expression of FGFR3 nor the overexpression of wild-type or truncated forms of MMSET influence the poor prognosis associated with this translocation.
Identification of Potential t(4;14) target genes
A number of genes flanking the genomic breakpoints at 4p16 have been suggested as potential t(4;14) target genes. Our working hypothesis was that a t(4;14) target gene would be over or under expressed at the mRNA level in all t(4;14)
POS samples. As the effects of the mu and 3' alpha IgH enhancers may act over large distances we identified all known genes within the 0.5 Mb region of 4p16.3 surrounding the translocation breakpoint sites ( Figure 1A ). We initiated the study with all previously proposed target genes with the intention of expanding our analysis if our most distant telomeric or centromic genes fit the hypothesis.
The pilot experiments in a small panel of MM cell lines identified TACC3, FGFR3, LETM1, MMSET Total, and RE-IIBP as potential t(4;14) target genes dysregulated as a result of t(4;14)( Table 2) . As TACC3 and WHSC2, our most distant telomeric and centromeric gene respectively, did not fit our working hypothesis, we moved the study into patient samples and did not expand our analysis to other genes. The expression of potential target genes in a patient population was determined from CD138 positive plasma cells isolated from diagnostic or relapse BM samples of 17 MM patients, of which 6 are t(4;14) POS and 11 are t(4;14)
NEG . For one of the t(4;14) POS patients we
For personal use only. on April 14, 2017. by guest www.bloodjournal.org From purified both the diagnostic and relapse sample, bringing the total number of purified BM samples to 18. This cohort includes both diagnostic and relapse samples, and the t(4;14)
POS patients included equal numbers of FGFR3 expressers and non-expressers.
As The truncated MB4-2/MB4-3 breakpoint variants were localized using the Cterminal tagged constructs. All four variants, both type I and II from each of the MB4-2 and MB4-3 genomic breakpoints, localized to the nucleus. However, unlike the wildtype/MB4-1 proteins that contain the N-terminus of MMSET, all four breakpoint variants are enriched in nucleoli ( Figure 5B ). Interestingly, in both MB4-2 and MB4-3 patients the only identified domain lost from MMSET is the N-terminal PWWP domain ( Figure   1C ). In MB4-3 patients the entire domain is lost, while in MB4-2 patients a part of the domain is maintained, however, the P-W-W-P motif is lost. Therefore, it appears that either the N-terminal PWWP domain or a yet unidentified domain in the N-terminus of MMSET regulates its localization. Based on localization, it appears that MMSET variants from MB4-1 patients may function differently from those expressed in MB4-2 and MB4-3 patients.
Characterization of a novel localization domain within MMSET
The mechanism controlling the localization differences appears to be encoded by 
Kinetics of MMSET Variants
The The FRAP recovery kinetics of the N-terminal tagged MMSET variants showed the predicted results, as the protein size increased (MMSET III/MMSET I/MMSET II) the t 1/2 times increased, due in part, to diffusion kinetics of larger molecules (Table 4) .
However, the t 1/2 of MMSET II, compared to MMSET I, was much slower (150 vs 4 seconds) than predicted by simple diffusion kinetics. These differential kinetics suggest that MMSET II, but not MMSET I, is binding to a nucleoplasmic structure with very high affinity.
The C-terminal tagged MB4-2 and MB4-3 breakpoint variants were compared to the similarly tagged wildtype/MB4-1 MMSET variants. For both MMSET I and II constructs, the t 1/2 times were faster for the C-terminal tags as compared to the N-terminal tags, however, the difference was not statistically significant ( Table 4 isoforms, [30] [31] [32] [33] indicates that this may be a valid therapeutic target in the rare patients with activating mutations, which may reflect disease progression events. 16 We hypothesized that true target genes of t(4;14) should be uniformly Since the predominant localization of all MMSET variants is nuclear, the localization of RE-IIBP to cytoplasmic foci with a nucleolar pool was unexpected. This promoter in vitro and regulating IL-5 transcription in vivo. 25 However, our localization data would suggest this is a minor activity given that very little RE-IIBP localized to the nucleoplasm where this function is predicted to occur. Furthermore, the PWWP domain present in RE-IIBP is similar to the PWWP domain of DNA methyltransferase 3b (Dnmt3b), which binds DNA unspecifically. 39 Thus the function of RE-IIBP remains elusive and requires further study. Interestingly the overexpressed RE-IIBP transcripts detected in t(4;14) positive patients appear to be de novo transcription events originating from the RE-IIBP promoter and not IgH hybrid transcripts.
The mechanism by which t(4;14) contributes to myelomagenesis remains unclear, however, two different possibilities exist based on our observations. Based on a classic model of simple, direct gain of function, RE-IIBP is a likely candidate, as it is the only transcript and protein that is not functionally disrupted. Alternatively, RE-IIBP or the much more abundant MMSET I, and particularly MMSET II may act through indirect mechanisms (e.g., interfering or abrogating the normal function of MMSET or its important protein/chromatin partners). Support for this second hypothesis comes from the related gene MLL, which is dysregulated by over 40 different reciprocal fusion proteins resulting in proteins that have either nuclear or cytoplasmic localization, with no shared unifying properties. 42, 43 Recently it has been shown that all oncogenic forms of MLL retain an ability to interact with Menin, a product of the MEN1 tumor suppressor locus, whose loss phenocopies loss of MLL. 44 Future studies are required to determine which protein products of the MMSET locus and the mechanism by which they contribute to myelomagenesis.
Table 1. PCR Primer and Probe Sequences
Oligo Name Sequence ( shortened to allow the differences in the t 1/2 times to be more evident.
